You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞普生物(300119.SZ):伊爾舒(複方制黴菌素軟膏)取得獸藥產品批准文號
格隆匯 02-08 20:10

格隆匯2月8日丨瑞普生物(300119.SZ)公佈,公司全資子公司瑞普(天津)生物藥業有限公司近日獲得了由農業農村部核發的獸藥產品批准文號,商品名稱為伊爾舒,獸藥通用名稱為複方制黴菌素軟膏。

伊爾舒(複方制黴菌素軟膏)是四種原料復配而成的大複方製劑,可以抵抗細菌、真菌、寄生蟲以及瘙癢,是犬貓通用耳部外用軟膏製劑。

伊爾舒處方設計合理、容温範圍大,組方中驅蟲成分經過多次結晶純化,雜質含量小於1%,與市售進口製劑相比,安全性得到極大提升;活性組分的特殊晶癖結構,可控制晶體的生長方向及速度,保持膏體內晶體粒徑大小始終均一,具有易分散、不易沉降、長期儲存產品性能穩定等優點,在寒冷地區仍可保持良好的延展性和擴散性,與骨架結構形成黏附層,在保護破損耳道細胞的同時,可將藥物微粒導入病灶,全效解決犬貓複雜病因引起的耳道疾病。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account